Indivior Pharmaceuticals (INDV) Cost of Revenue (2024 - 2026)

Indivior Pharmaceuticals' Cost of Revenue history runs 3 years deep, the most recent figure standing at $40.0 million for Q1 2026.

• In Q1 2026, Cost of Revenue fell 9.09% year-over-year to $40.0 million; the TTM figure through Mar 2026 stood at $242.0 million (up 2.11% YoY), while the FY2025 annual figure was $246.0 million, up 6.49% from the prior year.
• Cost of Revenue was $40.0 million for Q1 2026 at Indivior Pharmaceuticals, down from $67.0 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $83.0 million in Q3 2025 to a low of $38.0 million in Q1 2024.
• Historically, Cost of Revenue has averaged $57.4 million across 3 years, with a median of $52.0 million in 2025.
• Biggest YoY gain for Cost of Revenue was 39.58% in 2025; the steepest drop was 34.18% in 2025.
• A 3-year view of Cost of Revenue shows it stood at $48.0 million in 2024, then jumped by 39.58% to $67.0 million in 2025, then plunged by 40.3% to $40.0 million in 2026.
• The last three Cost of Revenue figures came in at $40.0 million (Q1 2026), $67.0 million (Q4 2025), and $83.0 million (Q3 2025), per Business Quant data.